Why the route matters: the pharmacokinetics of vitamin C
The same molecule, the same dose, two different routes, and a difference of almost two orders of magnitude in the blood. It is the real argument for IV therapy — and also where the confusion starts.
There is a reasonable objection made to IV therapy that is worth taking seriously: if vitamin C can be taken by mouth and costs very little, what is the point of putting it in a vein? The answer is not marketing. It is pharmacokinetics, and it has been measured.
The gut has a ceiling
Vitamin C does not enter the body by free diffusion: a transporter moves it, SVCT1, and that transporter saturates. At oral doses of around 500 to 1,000 mg it reaches its maximum capacity. Beyond that, increasing the oral dose no longer increases proportionally what reaches the blood: the excess simply is not absorbed.
That ceiling can be put in numbers. In the reference work on vitamin C pharmacokinetics, an oral dose of 1.25 g produced a peak plasma concentration of 134.8 µmol/L. The same dose given intravenously: 885 µmol/L.
And there is the point: however high the oral dose, plasma concentration does not exceed that order of magnitude, because the bottleneck is in absorption and not in how much is swallowed.
The intravenous route does not have that bottleneck
Given directly into the bloodstream, vitamin C bypasses the intestinal transporter entirely. The consequence is arithmetic:
That is roughly sixty times the maximum concentration reachable by mouth. The route stops being a logistical detail and becomes the variable that determines the range in which the molecule can act. Millimolar concentrations are not reachable by mouth — full stop.
By mouth and in a vein are not two ways of giving the same thing. They are two different concentration ranges.
And this is where we have to slow down
Everything above is a solid pharmacokinetic fact. What does not follow from it is that a higher plasma concentration automatically produces a better clinical outcome. They are two claims of a different nature, and the second needs its own evidence, condition by condition.
The oncology literature is the clearest example of that separation. It has been documented that concentrations of the order of 1 to 5 mmol/L are selectively cytotoxic to tumor cells in vitro. It has also been documented that oral administration provided no benefit in cancer patients in controlled studies. And at the same time, reviews point out that the decisive piece is missing: placebo-controlled randomized trials, without which the placebo effect cannot be ruled out in the reported outcomes.
That is: plausible mechanism, a range reachable only intravenously, and outcome evidence that is still incomplete. All three are true at the same time. Anyone who shows you only the first is telling you a third of the matter.
What to do with this as a patient
The practical conclusion is less dramatic and more useful than what is usually sold: the intravenous route serves to reach a range that is unreachable by mouth. If the aim of the protocol does not require that range, the intravenous route adds nothing that an oral supplement does not do more cheaply and with less risk.
That is why the right question before an IV therapy is not "what does it contain?" but "why does this need to go into a vein?". If there is no specific answer, it probably does not.
Where the evidence stands
What the evidence supports
- That the intestinal transporter SVCT1 saturates at oral doses of around 500 to 1,000 mg, which imposes a ceiling on absorption.
- That an oral dose of 1.25 g reached 134.8 µmol/L in plasma against 885 µmol/L by the intravenous route.
- That the maximum tolerated oral dose predicts around 220 µmol/L, while 50 g intravenously reached around 13,400 µmol/L.
- That concentrations of the order of 1 to 5 mmol/L, reachable only intravenously, have been described as selectively cytotoxic to tumor cells in vitro.
What it does not yet
- A higher plasma concentration does not equal a better clinical outcome: that requires its own evidence for each condition.
- In oncology, placebo-controlled randomized trials are missing, so the placebo effect cannot be ruled out in the reported results.
- There is no evidence supporting IV therapy as a longevity intervention in healthy people.
- None of this establishes optimal dose, frequency or composition for a general well-being goal.
Sources
- Padayatty et al. — Vitamin C pharmacokinetics: implications for oral and intravenous use The reference work the figures in this article come from.
- High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer Review of mechanisms and of the millimolar range described in vitro.
- High-Dose Vitamin C in Advanced-Stage Cancer Patients Review noting the absence of placebo-controlled trials.
This article is general information. It does not replace a medical assessment, and none of its statements should be read as an indication for treatment.
Your data, not an average.
Everything explained here only means something when it is applied to one specific person. That is the starting point.
See the Precision Assessment
